Neuren: Upcoming Catalysts 2022-23, page-8

Hi Veecat

Without knowing details of your previous experiences I disagree that rollout will be slow if trof attains FDA approval. In fact I suspect it will be rapid - Acadia have made it clear a fast smooth launch is a priority, the Rett community is by all reports an educated motivated group and Hashan’s recent report mentions that his discussions with relevant physicians indicated near 100% of Rett patients will try the drug. He also made the point that availability of a drug to treat the condition will almost certainly lead to increased diagnosis of the condition and therefore greater target population.

I agree with your comment that there is a risk that further trials may be required in ROW out of FDA jurisdiction. Hopefully this is not the case!